IFN beta-1a IM | IFN beta-1b | Glatiramer acetate | IFN beta-1a SC | Natalizumab | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
All DMD users—n (%)a | 1,827 (22.4) | 902 (11.1) | 3,261 (40.0) | 1,725 (21.1) | 800 (9.8) | 8,145 | |||||
DMD monotherapy users—n (%) | 1,718 (22.0) | 842 (10.8) | 3,029 (38.8) | 1,544 (19.8) | 672 (8.6) | 7,805 | |||||
Characteristics of DMD monotherapy users in 2011 | |||||||||||
IFN beta-1a IM | IFN beta-1b | Glatiramer acetate | IFN beta-1a SC | Natalizumab | P value | ||||||
Demographics | |||||||||||
Gender n (%)b,c | 0.002 | ||||||||||
Female | 1,313 (76.4) | 622 (73.9) | 2,354 (77.7) | 1,122 (72.7) | 501 (74.6) | ||||||
Male | 404 (23.5) | 220 (26.1) | 675 (22.3) | 422 (27.3) | 171 (25.4) | ||||||
Mean [SD] ageb | 49.6 [10.1] | 47.5 [11.1] | 47.3 [11.0] | 45.2 [10.5] | 45.6 [10.1] | < 0.001 | |||||
Mean [SD] DMD claimsb,d | 9.21 [4.34] | 9.09 [3.91] | 5.95 [4.14] | 9.03 [4.10] | 8.92 [3.98] | < 0.001 | |||||
Mean [SD] days supplyb,d | 274.6 [93.4] | 265.3 [95.5] | 186.3 [122.3] | 260.9 [105.2] | 241.3 [107.8] | < 0.001 | |||||
Mean [SD] days until DMD startb,d | 45.80 [67.49] | 41.57 [62.24] | 76.43 [93.28] | 54.17 [77.80] | 49.05 [74.87] | < 0.001 | |||||
Disease sequelaeb | |||||||||||
Abnormality of gait | 104 (6.1) | 80 (9.5) | 247 (8.2) | 133 (8.6) | 107 (15.9) | < 0.001 | |||||
Ataxia | 20 (1.2) | 26 (3.1) | 68 (2.2) | 37 (2.4) | 29 (4.3) | < 0.001 | |||||
Burning, numbness, tingling sensations | 160 (9.3) | 80 (9.5) | 305 (10.1) | 174 (11.3) | 94 (14.0) | 0.008 | |||||
Convulsions | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA | |||||
Depression | 125 (7.3) | 74 (8.8) | 279 (9.2) | 143 (9.3) | 90 (13.4) | < 0.001 | |||||
Fecal incontinence | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA | |||||
Fibromyalgia/myalgia and myositis | 26 (1.5) | 15 (1.8) | 84 (2.8) | 27 (1.7) | 24 (3.6) | 0.003 | |||||
Malaise and fatigue | 209 (12.2) | 137 (16.3) | 493 (16.3) | 261 (16.9) | 187 (27.8) | < 0.001 | |||||
Optic neuritis | 2 (0.1) | 2 (0.2) | 4 (0.1) | 2 (0.1) | 2 (0.3) | 0.809 | |||||
Spasms | 33 (1.9) | 23 (2.7) | 73 (2.4) | 39 (2.5) | 37 (5.5) | < 0.001 | |||||
Trigeminal neuralgia | 14 (0.8) | 5 (0.6) | 30 (1.0) | 15 (1.0) | 9 (1.3) | 0.621 | |||||
Urinary incontinence | 31 (0.2) | 21 (0.2) | 61 (2.0) | 23 (1.5) | 29 (4.3) | < 0.001 | |||||
Voice disturbance | 4 (0.2) | 0 (0.0) | 6 (0.2) | 1 (0.1) | 2 (0.3) | 0.449 | |||||
MS charge components b | Mean [SD] ($) | % of Total | Mean [SD] ($) | % of Total | Mean [SD] ($) | % of Total | Mean [SD] ($) | % of Total | Mean [SD] ($) | % of Total | P value |
Inpatiente | 2,061 [12,706] | 4.5 | 3,093 [15,185] | 6.4 | 3,053 [18,590] | 7.9 | 2,557 [14,226] | 5.6 | 3,610 [17,308] | 4.4 | 0.155 |
Outpatiente | 6,485 [18,322] | 14.2 | 7,931 [27,432] | 16.3 | 7,736 [19,461] | 20.1 | 7,540 [22,866] | 16.4 | 23,702 [26,046] | 29.0 | < 0.001 |
Emergency roome | 15 [323] | 0.0 | 7 [97] | 0.0 | 27 [374] | 0.1 | 28 [364] | 0.1 | 60 [651] | 0.1 | 0.059 |
DMD | 37,209 [13,042] | 81.3 | 37,498 [14,007] | 77.3 | 27,694 [18,055] | 71.9 | 35,803 [14,766] | 78.0 | 54,255 [34,102] | 66.5 | < 0.001 |
Total | 45,770[25,674] | 100.0 | 48,529 [33,932] | 100.0 | 38,509 [32,570] | 100.0 | 45,928 [30,434] | 100.0 | 81,627 [42,528] | 100.0 | < 0.001 |